<DOC>
	<DOCNO>NCT00002791</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining radiation therapy one chemotherapy drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy plus radiation therapy follow surgery treating patient soft tissue sarcoma .</brief_summary>
	<brief_title>Chemotherapy Plus Radiation Therapy Followed Surgery Treating Patients With Soft Tissue Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : I. Assess whether patient high-grade soft tissue sarcoma ( STS ) treat neoadjuvant mesna/doxorubicin/ifosfamide/dacarbazine ( MAID ) plus radiotherapy cooperative group set exhibit response rate , toxicity , complication rate comparable see pilot data collect Massachusetts General Hospital . II . Assess local control local complication relate surgery neoadjuvant MAID plus radiotherapy patient . III . Develop tissue repository frozen STS ancillary genetic flow cytometric analysis tumor . IV . Form Intergroup Working Sarcoma Group develop patient base , relationship , support future development completion phase III study adjuvant therapy STS . OUTLINE : The follow acronym use : DOX Doxorubicin , NSC-123127 DTIC Dacarbazine , NSC-45388 EBRT External-Beam Radiotherapy ( equipment unspecified ) G-CSF Filgrastim ; Granulocyte Colony-Stimulating Factor ( Amgen ) , NSC-614629 IFF Ifosfamide , NSC-109724 MAID Mesna/DOX/IFF/DTIC Mesna Mercaptoethane sulfonate , NSC-113891 3-Drug Combination Chemotherapy plus Radiotherapy follow Surgery follow , indicate , Radiotherapy follow 3-Drug Combination Chemotherapy . MAID ; plus EBRT primary tumor suspect microscopic disease ; follow minimal wide surgical excision ; follow , positive margin , postoperative EBRT ; follow MAID . PROJECTED ACCRUAL : There 60 patient accrue study within 15 month .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm soft tissue sarcoma extremity body wall primary postoperatively recurrent tumor Biopsy require within 2 month prior entry Grade II III tumor , include AJCC stage IIB IIIB lesion least 8 cm diameter No 4 chest lesion great 3 mm diameter preoperative CT The following histology exclude : Angiosarcoma scalp face Chondrosarcoma Extraosseous Ewing 's sarcoma Head neck sarcoma Kaposi 's sarcoma Osteosarcoma Primitive neuroectodermal tumor Rhabdomyosarcoma Patients study also eligible Frozen Tumor Repository study ( protocol RTOG9308 ) PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 80 % 100 % Hematopoietic : WBC least 4,000/mm3 Platelet count least 150,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL SGOT great 50 U Renal : Creatinine great 1.5 mg/dL Cardiovascular : No congestive heart failure ( CHF ) within 6 month No myocardial infarction ( MI ) within 6 month No New York Heart Association class IIIV heart disease Left ventricular ejection fraction least 50 % MUGA echocardiogram If history CHF MI , criterion must meet within past 6 month Other : No contraindication surgery No uncontrolled bacterial , viral , fungal infection No serious medical psychiatric illness precludes inform consent limit survival le 2 year No second malignancy within 5 year except : Surgically treat situ cervical cancer Nonmelanomatous skin cancer Not pregnant nursing Negative pregnancy test require fertile woman within 7 day prior entry Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>stage II adult soft tissue sarcoma</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
</DOC>